By Brian Finrow and Jim Roberts
We just released a paper on the preclinical development of LMN-201, Lumen’s orally delivered cocktail of therapeutic proteins for preventing C. difficile infection. In the news release we also shared that LMN-201 met its primary endpoint in Cohort 1 of the ongoing Phase 1 pharmacokinetic dosing study. Full data from both will be released after peer review and completion of trial Cohort 2.
We are intensely proud of these results. As detailed below, no one has ever developed a drug like this before, and the results have implications for biopharmaceutical drug development far beyond Lumen Bio.
